Summary A tamoxifen resistant cell line (clone 9) has been isolated from the tamoxifen sensitive, hormone responsive MCF-7 breast carcinoma cell line after transfection with mixed cDNA libraries, followed by tamoxifen selection in the presence of oestrogens. Transfection was confirmed by Southern analysis with vector probes. Clone 9 in several-fold more resistant to tamoxifen and other anti-oestrogens than wild type cells when cultured either as a monolayer or as colonies in soft agar but retains oestrogen receptors. Clone 9 was less responsive to 17-p-oestradiol than were wild type MCF-7. In addition to showing in vitro tamoxifen resistance, clone 9 was also tamoxifen resistant in vivo when xenografted into the nude mouse. Culture medium conditioned by clone 9 cells stimulated quiescent cells of the same clone as well as wild type cells, whereas medium conditioned by wild type MCF-7 was inhibitory to both, suggesting that clone 9 may be secreting an autocrine growth factor. Clone 9 provides a novel model for further investigation of the mechanism of anti-oestrogen resistance that occurs without loss of oestrogen receptors. Preliminary results suggest that an autocrine growth stimulatory mechanism may be one pathway of such resistance.
Anti-hormonal therapy has proven a successful strategy in the treatment of breast cancer and its use in early disease prolongs survival. Thus, following surgery the anti-oestrogen tamoxifen is effective in extending both disease free and overall survival of primary breast cancer patients. Tamoxifen also induces tumour suppression in about 50% of the patients with advanced oestrogen receptor positive breast cancer (Collins et al., 1992; Manni, 1989) . A major drawback in the successful use of anti-oestrogen therapy has been the development of resistance to the drug. Nearly all patients with recurrent disease develop resistance after an initial response and in the case of adjuvant therapy, 40-50% of node positive cases still relapse and die. Some tamoxifen resistant tumours respond to a second line hormone manipulation . In this case approximately half of the previous responders respond a second time . In contrast, a second resistant subtype is unresponsive to all hormone manipulations despite continued expression of oestrogen receptors. The mechanisms of the latter resistance may include over expression of growth factors (Johnston et al., 1992; Cullen et al., 1992) or growth factor receptors (Nicholson et al., 1988 (Nicholson et al., , 1989 Wright et al., 1992) , change in tamoxifen metabolism , mutations in the oestrogen receptor (Graham et al., 1990; Pakdel & Katzenellenbogen, 1992) or oestrogen receptor splice variants (McGuire et al., 1991; Murphy & Dotzlaw, 1989; Scott et al., 1991) .
To further examine resistance to tamoxifen in the presence of oestrogen receptors, we have attempted transfection of tamoxifen resistance into the tamoxifen sensitive MCF-7 cell line. In view of the possibility that novel autocrine growth pathways may lead to tamoxifen resistance, a mixture of several cDNA libraries from hormone unresponsive cells was used in the transfection. As stimulation of some cell types with cytokines is known to induce expression of cell adhesion molecules and secreted growth factors, cDNA libraries from such stimulated cells were used. Tamoxifen selection was carried out in the presence of oestrogens to approximate as closely as possible to the situation in which resistance arises in vivo. Tamoxifen levels similar to those achieved in plasma in vivo with conventional dosage regimens were used (Lien et Correspondence: R. Bicknell. al., 1989) . We now report isolation of tamoxifen resistant MCF-7 cells following cDNA transfection of such cDNA libraries. One of the clones (clone 9) retains oestrogen receptors and shows cross resistance to 4-hydroxytamoxifen as well as to the new pure anti-oestrogen ICI 164,384. Clone 9 is the first breast carcinoma line to show resistance to tamoxifen both in vitro and in vivo while continuing to express oestrogen receptors, and provides an in vitro model with which to investigate the mechanism of such resistance. Sequential selection of transfectants for gpt and tamoxifen resistance. gpt selection After 24 h in DMEM/10% FCS, cells were subjected to mycophenolic acid selection in the following medium: DMEM/10% dialysed FCS supplemented with xanthine (250 ig ml1'), hypoxanthine (15 ig ml-'), thymidine (10 ig ml-'), mycophenolic acid (15 jig ml-') and aminopterin (2 jig ml-') for 14 days (Mulligan & Berg, 1981) . Then with the same media lacking aminopterin and with the mycophenolic acid concentration reduced to 10iLg ml-' for a further 14 days. At this point selection medium was removed and cells grown on for a further 10 days in DMEM/10% FCS by which time distinct colonies of transfectants were clearly visible. Typically each transfection gave rise to -104 colonies (i.e. a transfection efficiency of 0.05%). All cells were dead in the control (no DNA) transfection. Transfection with 300 V was optimal.
Materials and methods

Materials
Tamoxifen selection On completion of mycophenolic acid selection, the clones from transfected libraries were subjected to tamoxifen selection in situ as follows: DMEM/10% FCS supplemented with tamoxifen (1 jiM) for 14 days. Culture medium was replaced every 2 days. At this point the control gpt transfection contained a few small colonies. By contrast the 300 V library transfection contained ten rapidly growing colonies (i.e. tamoxifen resistance to one in two million) and the 330-390 V transfections a further ten colonies between them. All 20 colonies were removed by exposure to trypsin within stainless steel cloning rings and cultured in the continued presence of tamoxifen (1 jM) before freezing back. Clones 1, 3 and 9 showed the fastest growth in the presence of 1 jM tamoxifen and were selected for further study. After a further 3 months culture in the presence of tamoxifen (1 jM) they were phenotypically characterised.
Characterisation ofgrowth properties of transfectant clones relative to wild type MCF-7. 3H-methylthymidine uptake assay Mitogenesis assays were performed in 96 well tissue culture plates. MCF-7 wild type or transfectants were grown in oestrogen free conditions for 2 weeks before being seeded at 3,000 cells/well in 10% DCC treated FCS, left 24 h and then treated with 17-P-oestradiol (500 pM) with or without antioestrogen in fresh PRF DMEM/10% DCC treated FCS. 17-,B-oestradiol (500 pM) and anti-oestrogens were present for a further 4 days at which time cells were pulse labelled with 0.5 iLCi of 3H-methylthymidine per well for 4 h before being removed by treatment with trypsin and harvested with an automated 96 well harvester directly onto filter mats and counted in a Pharmacia-Wallac flat bed betaplate scintillation counter. All experiments were repeated at least once with similar results.
Cell counting to determine growth curves The indicated number of cells were seeded into six well tissue culture plates in PRF DMEM/10% DCC treated FCS. At appropriate times, cells were detached by exposure to trypsin and counted in a Coulter counter. Cells were fed with fresh PRF DMEM/10% DCC treated FCS, with or without inhibitors on days 3, 5 and 7.
Colony formation in soft agar Three thousand cells were suspended in 300 jl of 0.3% 'Difco' noble agar in PRF DMEM/10% DCC treated FCS and layered over 0.3 ml of a 0.6% agar-medium basal layer in 24 well tissue culture plates. Samples were then fed with PRF DMEM/10% DCC treated FCS supplemented with tamoxifen (0, 1, 5 or 10 jM) and incubated at 37°C for 17 days. Half of the samples were also supplemented with 17-0-oestradiol (1 nM). On day 17 the number of colonies >30-40 jLm in diameter was then counted by eye. The relative size of the colonies was also noted. All points were triplicates. Experiments were repeated twice.
DNA extraction and Southern blotting MCF-7 or transfectants (2 x 107 cells) were lifted with trypsin and pelleted. The pellet was washed with PBS (x 2) and then lysed with 4 ml of the following buffer 0.1 M NaCl, 0.01 M Tris-HCl, 0.025 M EDTA, pH 8 and 0.5% SDS. Proteinase K was added to 100 jig ml' and the solution incubated at 50°C overnight. RNase A (1 jig ml-') was added, followed by a further incubation at 37°C for 1 h. The DNA was then extracted sequentially with phenol, phenol/ chloroform (1:1) and then chloroform before dialysis against three changes of 10 mM Tris-HCl, 1 mM EDTA, pH 8. Isolated DNA was stored at 4°C.
Samples of DNA were restricted with SpeI/HindIII (to probe for the CMV promoter) with SacII/SpeI (to probe for supF) and with HindIII/BglIl (to probe for gpt). DNA (10 jg per lane) was electrophoresed in 0.7% agarose gels and transferred to 'HyBond' nylon membranes by capillary blotting using 0.4 M NaOH as convectant. Filters were prehybridised overnight at 72°C in 10% dextran sulphate, 10 x Denhardts solution (270 mM NaCl, 15 mM sodium phosphate, 1.5 mM EDTA, pH 7), 2% SDS and salmon sperm DNA (400 jg ml-'). Hybridisation was carried out overnight at 72°C under the same conditions as for pre-hybridisation, but including cDNA probes labelled by random priming. Filters were washed to a stringency of 0.1 x SSC, 1% SDS at 55°C and then exposed to preflashed film at -70°C. Probes were removed from filters by treatment with 0.4 M NaOH for 30 min at 45°C, followed by treatment with 0.2 M Tris-HCl, 0.1 x SSC, 0.1% SDS, pH 8 at 45°C for 30min.
Oestrogen and EGF receptor assay
The oestrogen receptor number in oestrogen-depleted cells was determined by the DCC ligand binding assay in accord with EORTC guidelines (EORTC, 1980) . Cytosolic fractions were prepared as previously described (Leake et al., 1981) from subconfluent cells. EGF receptors were measured by a competitive binding assay on membrane fractions (Smith et al., 1989) .
Conditioning of culture media by wild type MCF-7 and clone 9 transfectant Subconfluent cells were washed (x 3) with DMEM and then left for 48 h to condition DMEM. Media was collected and dialysed against water (x 3) with tubing of molecular weight cut-off 3.5 kDa. Protein was freeze dried, reconstituted with x 10 PRF DMEM and water to give a solution in PRF DMEM. 3H-methylthymidine assays were then performed as described above in 2% DCC treated FCS.
Xenografts in BALBc NuNu mice BALBc NuNu mice were ovariectomised and received two subcutaneous implants. One a 60-day release pellet containing 1.5 mg 17-p-oestradiol and the other 107 MCF-7 cells.
The pellet was placed at the back of the neck and the cells in the flank. Half of the mice then received twice weekly s.c.
injection of 100 jig tamoxifen in 200 jIl of sesame oil. The controls received sesame oil alone. Tumour measurements were performed twice weekly.
Results
Transfection of MCF-7 cells and Southern analysis
In preliminary experiments a tamoxifen selection protocol was developed such that of 2 x 107 wild type cells placed under selection, none survived and we were unable to deter-mine the frequency of spontaneous resistance. MCF-7 can give rise to spontaneously anti-oestrogen resistant lines (see e.g. Nawata et al., 1981) but it appears that many more cells have to be placed under selection. The selection protocol used here involved replacing the culture media every other day with fresh 10% FCS/DMEM containing 1 JAM tamoxifen.
After transfection of the cDNA libraries and mycophenolic acid selection the gpt control and the gpt/library transfection each gave rise to around 104 discrete colonies. These were subjected directly to tamoxifen selection in situ. At 14 days the gpt control showed only two remaining colonies that did not appear to be proliferating. By contrast, the library transfectants containing 20 rapidly growing colonies. Thus, 20 resistant clones were obtained from 104 transfectants, whereas wild type MCF-7 failed to give rise to any resistant clones from 2 x 107 cells. This argues strongly for resistance to have arisen as a result of the transfection event. Of the tamoxifen resistant transfectants, clones 1, 3 and in particular 9 were fast growing in the presence of 1 gM tamoxifen. These three clones were chosen for further characterisation. Figure  1 shows Southern analysis of DNA from these cells probed with (a) CMV promoter and (b) supF. Probing for the CMV promoter (Figure la) gave a strong-positive in clone 9, however, a weak band was also present in wild type cells, suggesting that they may contain CMV promoter sequences. The lane labelled T corresponds to a digest of DNA from a transient transfection of HL60 cells with pCDM8 and P to a digest of the plasmid pCDM8. In view of the weak signal for CMV sequences in wild type MCF-7, we also probed for the bacterial gene supF. Figure lb shows that supF is clearly present in clones 3 and 9 but absent from wild type MCF-7. We conclude that clones 3 and 9 are stable transfectants. Probing for gpt showed this to be absent in wild type MCF-7, but present in all transfectants (data not shown), consistent with their growth under mycophenolic acid selection.
Effect of the anti-oestrogens tamoxifen, 4-hydroxytamoxifen and ICI 164,384 on 3H-methylthymidine uptake and growth of MCF-7 wild type and clone 9 cells The effect of 17-,-oestradiol and of anti-oestrogens on 3H-methylthymidine uptake and on growth of MCF-7 wild type and clone 9 cells was examined in PRF DMEM/10% DCC treated FCS after culture of the cells in this media for 2 weeks to deprive them of oestrogens. experiment to avoid any effects of variation in growth rates in the first few days of the experiment. Clone 9 was seen to be markedly more resistant to the growth inhibitory effect of tamoxifen and 4-hydroxytamoxifen than were wild type cells.
Substantial inhibition of wild type growth was seen in 10-8 M 4-hydroxytamoxifen whereas higher concentrations of 4-hydroxytamoxifen (10-6 M) were required to see similar inhibition in clone 9. Clone 9 is more resistant to ICI 164,384 than wild type cells but appears less so than it is to the other two anti-oestrogens. Growth curves confirmed that the effects on 3H-methylthymidine uptake reflect true effects on cell growth. Thus, Figure 3a shows that wild type cells are stimulated by 17-,-oestradiol (Figure 5a ). These findings raise the possibility that the resistance of Day clone 9 to 1 and 5 fLM tamoxifen is due simply to its faster growth rate or greater colony forming ability. This is not the anti-oestrogens on growth curves for MCF-7 case, for, as shown in Figure Sb ing at day 1. Cells we re-fed with fresh was substantially more resistant than either wild type or ni-oestrogen in PRF DMEM/10% DCC treat-clone 3 (data not shown). Resistance was particularly striking 5 and 7 (mean±Rs.d., n = 2).
in the absence of 17-p-oestradiol. Colony formation by clone 9 in the absence of oestragens may be a component of the tamoxifen resistant phenotype.
reduces proliferation below that in the PRF DMEM control suggests that there remains residual oestrogen in the culture medium. Figure 3b shows that oestrogen had no detectable effect on the rate of growth of clone 9. By contrast, clone 9 continues to show substantial growth in the presence of all three anti-oestrogens. The growth in the presence of ICI 164,384 is particularly interesting in view of the lower level of resistance shown by clone 9 in the 3H-methylthymidine uptake assay (Figure 2c ). To confirm that clone 9 is less responsive to oestrogen we examined 3H-methylthymidine uptake in response to oestradiol. Figure 4 shows that the percentage stimulation of clone 9 by oestradiol is less (+8%) than that maximally seen with MCF-7 wild type cells (+25%). This accords with the poor stimulation of clone 9 growth by 17-f-oestradiol (Figure 3b ).
Colony formation in soft agar
The growth of MCF-7 wild type and clone 9 cells in soft agar was examined in PRF DMEM/10% DCC treated FCS in the presence of 0, 1 and 5 i4M tamoxifen ( Figure Sa) . Half of the samples also received 17-p-oestradiol (1 nM). Differences were apparent between the wild type and clone 9 cells. Not only were there many more colonies of clone 9 cells but the colony size was larger relative to controls (Figure 6 ). Clone 9 also Effect of media conditioned by wild type MCF-7 and clone 9 on 3H-methylthymidine uptake by both cell lines DMEM was conditioned by cultures of MCF-7 wild type and clone 9 cells under identical conditions. These media were then dialysed, freeze dried and reconstituted to give a solution in PRF DMEM/2% DCC treated FCS. These media were tested for their effects on 3H-methylthymidine uptake in both MCF-7 wild type and clone 9 cells. Figure 7 shows that medium conditioned by wild type MCF-7 was inhibitory to both wild type MCF-7 and clone 9. This presumably reflects the activity of inhibitory cytokines outweighing that of stimulatory cytokines e.g. MCF-7 are known to produce and to be inhibited by TGF-P, (Zugmaier et al., 1989; Knabbe et al., 1987) . In contrast medium conditioned by clone 9 stimulated 3H-methylthymidine uptake in both cell types when compared to PRF DMEM/2% DCC treated FCS controls. We conclude that transfection has induced secretion of a mitogen (or reduced secretion of an inhibitor) by the MCF-7 cells.
Oestrogen and EGF receptor expression
The data in Table I shows that there was a small decrease in the oestrogen and a somewhat larger decrease in the EGF imately 50-60% response rate). While the majority relapse within 2 years, if treated with a second anti-hormonal therapy, approximately 50% may respond again . Oestrogen receptors are detectable in patients relapsing on tamoxifen, but not all of these respond to second line therapy (Leake et al., 1981; Taylor et al., 1982) . It is this latter group of patients with oestrogen receptor positive tumours failing tamoxifen after an initial response, and not responding to further endocrine manipulation, who present a major clinical problem. Clone 9 has a phenotype that makes it a suitable model with which to investigate the mechanism(s) of such resistance. The parent MCF-7 cells that were transfected are hormone responsive and antioestrogen sensitive. Clone 9 responds to anti-oestrogens but requires higher doses for inhibition than do wild type cells. Clone 9 also grows in vitro but not in vivo in the absence of oestrogen. The latter apparent discrepancy indicates that while oestrogen is not needed for growth of clone 9 it is needed for successful tumour formation. It is possible that oestrogen stimulates release of, for example, an angiogenic factor or protease (e.g. stromolysin) which is essential for tumour formation but that has no effect on the in vitro growth rate of the cells.
Oestrogen receptors were detectable in clone 9 by ligand binding (Table I) and we conclude that a major deficiency in hormone binding does not account for resistance. Although oestrogen receptors were lower in clone 9, the level of expression is well within the range associated with hormone responsiveness (Bezwoda et al., 1991) . Further, resistance to three anti-oestrogens, including ICI 164,384 which is thought to exert its anti-oestrogenic effect by a different mechanism to that of tamoxifen (Dauvois et al., 1992) , is consistent with resistance not arising from mutation in the oestrogen receptor.
Inhibitory growth factors are an important pathway by which tamoxifen is thought to mediate its effect (Knabbe et al., 1987; Colletta et al., 1990) . The secretion of active TGF-PI, an inhibitor of breast carcinoma cells in culture (Zugmaier et al., 1989; Knabbe et al., 1987; Toi et al., 1992) is induced by tamoxifen (Knabbe et al., 1987) (Lien et al., 1989) , was 20% for clone 9 vs 100% for wild type MCF-7 i.e. a 5-fold difference. When growth curves were determined by cell counting, inhibition at day 9 of oestrogen stimulated growth was complete with wild type cells but clone 9 was unaffected (Figure 3 ).
Oestrogen hypersensitivity could also account for some of the featues of clone 9, with minute amounts residual in DCC treated FCS or carried over in cells causing apparent hormone 'independent' growth. Dose response curves to oestradiol showed this was not the case, however, and that clone 9 actually has a reduced response to 17-p-oestradiol (Figure 4) (Osborne et al., 1991 Weibe et al., 1992 (Nicholson et al., 1988 (Nicholson et al., , 1989 (Valverius et al., 1990) claims that high level expression of the receptor failed to alter hormone dependency or tamoxifen sensitivity, a second study (van Agthoven et al., 1992) has disagreed. We conclude that in vivo EGF receptor expression erbB-2 expression plays a complex and possibly paracrine role in the evolution (Nicholson et into MCF-7 cells. Transfectants exhibited a considerably reduced response to oestrogen but inhibition by tamoxifen was unchanged (Daly et al., 1991) . Transfection of v-rasH into MCF-7 cells was reported to confer hormone independent growth (Kasid et al., 1985) . However, this result has been challenged by others who followed a similar strategy but were unable to obtain hormone independent clones (Sommers et al., 1990; Sukumar et al., 1988) . It can be seen from Table II that none of the cell lines have phenotypes comparable to clone 9 which shows resistance to 4-hydroxytamoxifen, ICI 164,384, down-regulation of EGF receptors, hormone independent growth in soft agar and tamoxifen resistance in vivo.
Although clone 9 was isolated after DNA transfection, this does not prove that the resistance is due to transfection. However, there are clearly vector sequences present based on detection of the bacterial gene supF in clone 9 but not in wild type MCF-7 (Figure lb) . We are currently attempting to identify a transfected gene that may give rise to tamoxifen resistance in clone 9 cells. The involvement of such a gene in breast cancer tamoxifen resistance would then need to be examined.
Understanding the mechanisms of hormone resistance is of increasing importance in view of the widespread use of tamoxifen in adjuvant therapy (Collins et al., 1992) . A knowledge of the mechanism will allow the development of new therapeutic approaches for this particular subgroup of patients resistant to hormone therapy i.e. those with oestrogen receptor positive tumours that are unresponsive to aromatase inhibitors and to second line hormone therapy.
